Eli Lilly and Company (NYSE: LLY) revealed encouraging findings from a Phase 2 clinical trial for their experimental medication, eloralintide, showing notable weight loss and a good tolerability profile in overweight or obese people.
The safety and effectiveness of the once-weekly, selective amylin receptor agonist eloralintide were assessed in a 48-week, randomised, double-blind, placebo-controlled research (NCT06230523). 263 obese or overweight individuals without type 2 diabetes who had at least one weight-related condition were included in the study.
Key Efficacy and Safety Findings
All eloralintide doses demonstrated significantly better mean weight reductions from baseline when compared to placebo, meeting the study’s main objective.
Participants on eloralintide experienced dose-dependent mean weight decreases at 48 weeks, ranging from 9.5% to 20.1%. The placebo group, on the other hand, only had a 0.4% mean weight loss.
Read More: Eli Lilly Partners with NVIDIA to Build Pharma’s Most Powerful AI Supercomputer
Detailed Weight Loss Results by Dose (at 48 weeks)
- 9 mg: average weight loss of 20.1%
- 6 mg: average weight loss of 18.0%
- 3 mg: average weight loss of 12.4%
- 1 mg: average weight loss of 9.5%
- Placebo: average weight loss of 0.4%
Eloralintide therapy was linked to benefits in a number of cardiometabolic risk variables in addition to weight loss, such as decreased waist circumference, lowered blood pressure, improved lipid profiles, and improved glycaemic management.
Crucially, the medication showed a “favourable tolerability profile.” Fatigue and mild-to-moderate gastrointestinal problems like nausea were the most often reported side effects. At the lower 1 mg and 3 mg dosages, the incidence of these adverse effects was found to be comparable to a placebo, and it decreased with slower dose escalation techniques.
Read More: Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial
A New Mechanism for Weight Management
Eloralintide, also referred to as LY3841136, belongs to a group of medications called amylin receptor agonists. It is made to be extremely selective for the amylin receptor, which is thought to be crucial for controlling hunger and fullness. The medication increases feelings of fullness by imitating the natural hormone amylin, which may result in a reduction in caloric consumption.
Compared to the popular incretin-based treatments, including GLP-1 receptor agonists, this mechanism provides an alternative approach to treating obesity.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
Future Plans
The drug’s advancement into late-stage development is supported by the positive Phase 2 results, which were reported in The Lancet and presented at the ObesityWeek 2025 conference. Eli Lilly declared that by the end of 2025, eloralintide Phase 3 trial enrolment will begin.
In order to assess eloralintide as a stand-alone treatment and in conjunction with tirzepatide (Lilly’s dual GIP/GLP-1 agonist) for weight management in people with obesity or overweight who also have type 2 diabetes, the company is also undertaking a separate Phase 2 research (NCT06603571).
Last Modified:
